FDA Expands Guselkumab Label in PsA - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

  • By

  • Kathryn Wighton

  • May 29, 2026

  • 2 min

Share

Objective:

To inform about the FDA's approval of guselkumab for inhibiting structural joint damage in adults with active psoriatic arthritis.

Key Findings:
  • Guselkumab met the primary endpoint of reducing joint symptoms.
  • It also met a major secondary endpoint of inhibiting progression of structural damage compared with placebo.
  • Patients switching from placebo to guselkumab at week 24 had a 57% reduction in radiographic progression from weeks 24 to 48.
  • No new safety signals were identified, consistent with the established safety profile of guselkumab.
Interpretation:

Limitations:
Conclusion:

Original Source(s)

FDA Expands Guselkumab Label in PsA

  • by Kathryn Wighton

  • May 29, 2026

Related Content

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.

Muscle recovery following knee arthroplasty

Investigators assessed changes in quadriceps and hamstring strength and flexibility through 12 months following total knee arthroplasty.

Cumulative training load may signal musculoskeletal injury

Wearable sensor measures showed associations with musculoskeletal injury, but evidence certainty remained very low.